Vascular Biogenics Profit Margin 2013-2021 | VBLT
Current and historical gross margin, operating margin and net profit margin for Vascular Biogenics (VBLT) over the last 10 years. Profit margin can be defined as the percentage of revenue that a company retains as income after the deduction of expenses. Vascular Biogenics net profit margin as of June 30, 2021 is -3546.69%.
|Vascular Biogenics Annual Profit Margins
|Vascular Biogenics Quarterly Profit Margins
||Medical - Biomedical and Genetics
Vascular Biogenics Ltd. is a clinical stage biotechnology company. It is focused on the discovery, development and commercialization of treatments for cancer and immune-inflammatory diseases. Its lead oncology candidate VB-111, is a gene-based biologic which is in Phase II clinical trials for the treatment of recurrent glioblastoma, an aggressive form of brain cancer. It is also developing VB-201, an oral small molecule that is in Phase II clinical trials for the treatment psoriasis and ulcerative colitis. Vascular Biogenics Ltd. is headquartered in Or Yehuda, Israel.